KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Francesco Ferrucci, Pier; Maria Di Giacomo, Anna; Del Vecchio, Michele; Atkinson, Victoria; Schmidt, Henrik; Schachter, Jacob; Queirolo, Paola; V. Long, Georgina; Stephens, Rosalie; Marie Svane, Inge; Lotem, Michal; Abu-Amna, Mahmoud; Gasal, Eduard; Ghori, Razi; J. Diede, Scott; Croydon, Elizabeth; Ribas, Antoni; A. Ascierto, Paolo

doi:10.1136/jitc-2020-001806

Public

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Published in Journal for ImmunoTherapy of Cancer • Dec 1, 2020

Authors:

Pier Francesco Ferrucci

Anna Maria Di Giacomo

Michele Del Vecchio

Abstract

BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall surv...

Subject

Dabrafenib

Trametinib

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!